Robert R. Ruffolo - 11 Aug 2023 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 11 Aug 2023
Net transaction value: -$36,144
SEC form: 4
Accepted by SEC: 11 Aug 2023, 16:10:27 UTC
Prior SEC filing: 07 Jun 2023
Next SEC filing: 29 Dec 2023
Source filing: View source filing
Reporting owner signature: /s/ Matthew Kowalsky, Attorney-in-Fact

Key filing fact

Robert R. Ruffolo filed Form 4 for Sigilon Therapeutics, Inc. on 11 Aug 2023.

Key facts

This page summarizes Robert R. Ruffolo's Form 4 filing for Sigilon Therapeutics, Inc..
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 11 Aug 2023, 16:10.

Change

Previous filing in this sequence was filed on 07 Jun 2023.
Current net transaction value: -$36,144.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGTX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $4,538
Shares: -683
Change %: -100%
Price: $6.64^*
Shares after: 0
Date: 11 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 683
Exercise price: $8.28
Footnotes: F1, F2

SGTX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $3,414
Shares: -683
Change %: -100%
Price: $5.00^*
Shares after: 0
Date: 11 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 683
Exercise price: $9.92
Footnotes: F1, F2

SGTX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $28,193
Shares: -3,754
Change %: -100%
Price: $7.51^*
Shares after: 0
Date: 11 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,754
Exercise price: $7.41
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.

Footnote F2

Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time.

SEC remarks

Capitalized terms used herein without definition have the meanings ascribed to them in the Agreement and Plan of Merger, dated as of June 28, 2023, among Sigilon Therapeutics, Inc., Eli Lilly and Company and Shenandoah Acquisition Corporation. (the "Merger Agreement").